Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sezary syndrome. Molloy K, Vico C, Ortiz-Romero PL, Scarisbrick JJ, et al. Br J Dermatol 2021;184:978-981.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Molloy K, Vico C, Ortiz-Romero PL, Scarisbrick JJ, et al. Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sezary syndrome. Br J Dermatol 2021;184:978-981.
PMID: 33314065